However, although Ugurel’s study could have the advantage of a rapid analysis of the serum levels of the two biomarkers, the categorization of MM patients into PD1 low and PD-L1 low vs PD1 high and/or PD-L1 high selects a small number of patients in the cohort compared to the total enrolled in the study and therefore does not reflect the totality of the responses to anti PD1 therapy. This evidence concerns the gene PDCD1 and Miyoshi myopathy.